医药生物行业周报:坚定看好医药板块回暖 重申投资临床价值三段论

光大证券
Mar 01

行情回顾:上周A 股医药生物(申万,下同)指数上涨0.50%,跑输沪深300指数0.58pp,跑输创业板综指1.82pp,在31 个子行业中排名第25。港股恒生医疗健康指数上周收跌6.07%,跑输恒生国企指数4.96pp。研发进展:上周,康哲药业的CMS-D008 注射液、康辰药业的KC1036 片的临床申请新进承办;海思科的HSK46575 片、百利天恒的注射用伦康依隆妥单抗和注射用BL-...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10